Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.

Personalized medicine - 1 Dec 2025

Abderahmene Amani, Francke Marith I, Ammar Meriam, Andrews Louise M, Hesselink Dennis A, Amor Dorra, Sahtout Wissal, Awatif Azzabi, Bouslama Ali, Zellama Dorsaf, Omezzine Asma, De Winter Brenda C M

Abstract excerpt

INTRODUCTION: Tacrolimus is the cornerstone of immunosuppressive therapy in kidney transplantation. However, it exhibits significant pharmacokinetic (PK) variability among patients. Therefore, Population Pharmacokinetic (PopPK) modeling is crucial for personalized tacrolimus treatment. While PopPK models have been extensively developed for transplant patients in Asian and Caucasian populations, it is true that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Mass Index
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Tacrolimus

Share to Transplant Recipients

Share to Tunisia

Source

Identifiers

PMID: 41486946
DOI: 10.1080/17410541.2025.2606641

Genes

CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.PMID 41486946Read ↗

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus for Tunisian Adults after Renal Transplantation.Semantic proximity Read ↗

Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.Semantic proximity Read ↗

Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.Semantic proximity Read ↗

Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.Semantic proximity Read ↗

Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review.Semantic proximity Read ↗

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.Semantic proximity Read ↗

Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients.Semantic proximity Read ↗

Population Pharmacokinetic Models for Tacrolimus in non-transplant patients: A Systematic ReviewSemantic proximity Read ↗

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Semantic proximity Read ↗

Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.